339 related articles for article (PubMed ID: 20879880)
1. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
Baker DL; Schmidt ML; Cohn SL; Maris JM; London WB; Buxton A; Stram D; Castleberry RP; Shimada H; Sandler A; Shamberger RC; Look AT; Reynolds CP; Seeger RC; Matthay KK;
N Engl J Med; 2010 Sep; 363(14):1313-23. PubMed ID: 20879880
[TBL] [Abstract][Full Text] [Related]
2. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
Twist CJ; Naranjo A; Schmidt ML; Tenney SC; Cohn SL; Meany HJ; Mattei P; Adkins ES; Shimada H; London WB; Park JR; Matthay KK; Maris JM
J Clin Oncol; 2019 Jan; 37(2):115-124. PubMed ID: 30444686
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
[TBL] [Abstract][Full Text] [Related]
4. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Twist CJ; Schmidt ML; Naranjo A; London WB; Tenney SC; Marachelian A; Shimada H; Collins MH; Esiashvili N; Adkins ES; Mattei P; Handler M; Katzenstein H; Attiyeh E; Hogarty MD; Gastier-Foster J; Wagner E; Matthay KK; Park JR; Maris JM; Cohn SL
J Clin Oncol; 2019 Dec; 37(34):3243-3255. PubMed ID: 31386611
[TBL] [Abstract][Full Text] [Related]
5. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.
Bowman LC; Castleberry RP; Cantor A; Joshi V; Cohn SL; Smith EI; Yu A; Brodeur GM; Hayes FA; Look AT
J Natl Cancer Inst; 1997 Mar; 89(5):373-80. PubMed ID: 9060959
[TBL] [Abstract][Full Text] [Related]
6. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
7. Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt.
Elzomor H; Ahmed G; Elmenawi S; Elkinaai N; Refaat A; Soliman S; Abdelwahab MA; Zaghloul MS; Fawzy M
J Egypt Natl Canc Inst; 2018 Mar; 30(1):21-26. PubMed ID: 29428371
[TBL] [Abstract][Full Text] [Related]
8. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
9. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
[TBL] [Abstract][Full Text] [Related]
10. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
11. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma.
Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
[TBL] [Abstract][Full Text] [Related]
13. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
14. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.
Garaventa A; Boni L; Lo Piccolo MS; Tonini GP; Gambini C; Mancini A; Tonegatti L; Carli M; di Montezemolo LC; Di Cataldo A; Casale F; Mazzocco K; Cecchetto G; Rizzo A; Bernardi B;
Ann Oncol; 2002 Jun; 13(6):956-64. PubMed ID: 12123342
[TBL] [Abstract][Full Text] [Related]
15. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O;
Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
17. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN
J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023
[TBL] [Abstract][Full Text] [Related]
19. Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee.
Iehara T; Yoneda A; Yokota I; Takahashi H; Teramukai S; Kamijyo T; Nakazawa A; Takimoto T; Kikuta A; Yagyu S; Ikeda H; Nakagawara A; Tajiri T;
Pediatr Blood Cancer; 2019 Nov; 66(11):e27914. PubMed ID: 31342649
[TBL] [Abstract][Full Text] [Related]
20. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
